Abstract: Diabetes is a major risk factor for the development of heart failure. One of the hallmarks of diabetes is insulin resistance associated with hyperinsulinemia. The literature shows that insulin and adrenergic signaling is intimately linked to each other; however, whether and how insulin may modulate cardiac adrenergic signaling and cardiac function remains unknown. Notably, recent studies have revealed that insulin receptor and b 2 adrenergic receptor (b 2 AR) forms a membrane complex in animal hearts, bringing together the direct contact between 2 receptor signaling systems, and forming an integrated and dynamic network. Moreover, insulin can drive cardiac adrenergic desensitization via protein kinase A and G protein-receptor kinases phosphorylation of the b 2 AR, which compromises adrenergic regulation of cardiac contractile function. In this review, we will explore the current state of knowledge linking insulin and G protein-coupled receptor signaling, especially b-adrenergic receptor signaling in the heart, with emphasis on molecular insights regarding its role in diabetic cardiomyopathy.
INTRODUCTION
Diabetes is a major risk factor for development of heart failure (HF). 1 The Framingham study shows that independent of age, obesity, or dyslipidemia, diabetes alone is linked with a 2-fold increased risk of HF in men and a 5-fold increased risk in women. 2 There is evidence that diabetes itself is an independent significant predictor of poor outcomes in HF. 3, 4 The association between diabetes and cardiac dysfunction in humans is also supported by data from animal models, which demonstrate distinct diabetes-induced cardiac structural, metabolic, and functional changes, as well as changes in vascular reactivity. 5, 6 The impact of generalized type 2 diabetes mellitus (T2DM) metabolic disorders (including insulin resistance, reduced glucose clearance, and increased circulating fatty acids) on the cardiovascular system is complex. A common feature of T2DM is hyperinsulinemia, which results from a chronically insulin-resistant state. 7 Insulin controls a wide variety of biological processes by acting on its receptor tyrosine kinase (RTK). Receptor activation initiates a cascade of phosphorylation events leading to the activation of enzymes that control many aspects of metabolism and growth. 8 In the heart, insulin regulates various physiological and pathophysiological functions, including myocardial energy metabolism, contractility, protein expression, growth and hypertrophy, and ion transport. 9, 10 However, the impact of insulin on the development of diabetes mellitus (DM)-associated cardiomyopathy is not yet well defined. Cardiovascular homeostasis is regulated by a diverse array of hormones and neurotransmitters, many of which exert their physiological effects through activation of G proteincoupled receptors (GPCRs). Activation of GPCRs initiates cascades of signaling pathways, which modulate critical functional parameters such as heart rate, contractility, vascular tone, and blood volume, and promotes cardiac hypertrophy by phosphorylation of transcriptional factors and changes in gene expression. Thus, abnormal GPCR signaling is a common feature of many chronic cardiovascular pathologies such as hypertension, 11 HF, 12, 13 and cardiomyopathy, 14 making GPCRs an important target for cardiac drug therapy.
GPCRs and RTKs are transmembrane receptors that initiate 2 major intracellular signaling cascades in response to a diverse array of ligands. Recent studies have shown several different styles of cross-talk between GPCR-and RTK-initiated pathways, with GPCRs or components of GPCR-induced pathways being either upstream or downstream of RTKs. [15] [16] [17] [18] GPCRs that are reported to be regulated by RTKs include angiotensin, 19 endothelin, 16 thrombin, 17 a 1 -adrenergic, 20 and b 2 -adrenergic receptors. 15, 18 RTKs use several components of GPCR signaling, such as b-arrestin, G protein-receptor kinases (GRKs), and regulator of G protein signaling causing integration of the signaling pathways. 21 For example, insulin has been shown to induce tissue RAS activation directly 22 and to cause increases in the AT1 receptor expression in cultured vascular cells. 23 Earlier studies revealed that insulin counter-regulates the action of b-adrenergic catecholamine stimulation, at a point proximal to b-adrenergic receptors (bARs). 24 Yu et al 25 reports that insulin attenuates the contractile response to bAR stimulation and suppresses isoproterenol (ISO)-induced cardiac dysfunction and cell injury in myocardial ischemia/reperfusion (I/R). Phosphatidylinositol 3-kinase (PI3K), a downstream kinase in the insulin signaling pathway, inhibits bAR stimulationinduced contractile responses in isolated cardiomyocytes 26 and confines and negates the concurrent b 2 AR/Gs-mediated protein kinase A (PKA) signaling. 27 Experimentally-induced diabetes increases a 1 -adrenergic sensitivity of rat atria possibly because of an increased receptor affinity, but these changes can be reversed with insulin treatment. 28 Insulin also induces concentration-dependent increases in the phosphorylation state of the a 1B -ARs in Rat-1 cells. The cells stimulated by insulin show loss of function and increased a 1B -AR phosphorylation and internalization, suggesting that GPCRs themselves may act as substrates for the insulin receptor (InsR). 29 These studies indicate that the mechanism(s) by which insulin affects GPCR signaling remain poorly understood. Understanding the molecular details of insulin regulation of GPCR signaling pathways in the cardiovascular system has become particularly important to understand the mechanism of diabetic cardiomyopathy (DCM). In this review, we will explore the current state of knowledge linking insulin and GPCRs signaling, especially bAR signaling in the heart, with emphasis on molecular insights regarding its role in DCM (See Table 1 for summary).
INSULIN REGULATES bAR SIGNALING
Biochemically, InsRs and bARs induce heterologous signal transduction pathways leading to divergent and sometimes opposing cellular processes. InsRs, which belong to RTK family, phosphorylate insulin receptor substrates (IRSs1/2) leading to 2 major signaling branches, the Grb2-depdendent mitogen-activated protein kinase (MAPK) activation and PI3K-dependent Akt activation. The IRS1-induced and PI3K-mediated Akt activity promotes GLUT4 translocation in cardiac and skeletal muscle cells, therefore increasing glucose uptake and oxidation. The insulin-induced Akt activity promotes cardiac hypertrophy. 30, 31 Ligand binding to bARs, which are prototypical members of the GPCR superfamily, induces cAMP-dependent PKA activation and phosphorylation of various substrates such as phospholamban (PLB) leading to increased activities of SERCA2 and RyR2. [32] [33] [34] Enhanced SERCA and RyR2 activities increase myocyte contractility, stroke volume, and cardiac output. 34 Studies in adipocytes and liver cells have suggested that insulin and adrenergic stimulation act reciprocally to blunt each other's signaling. 35 We have recently published evidence showing that insulin impairs myocardial contractility via a mechanism of inducing a Gibiased b 2 -adrenergic signal that inhibits cAMP generation and cardiac contractility induced by bAR stimulation 36 (Fig.   1 ). Because downstream effector pathways for both InsR and GPCRs share common points/nodes that are essential to regulation of cell proliferation, differentiation, and metabolism, the counter-regulation of insulin on bARs could happen at multiple levels of each pathway/cascade involving distinct molecules (eg, receptors, effectors, adaptors, and scaffolds). Notably, recent studies reveal that InsR and b 2 AR forms a membrane complex in animal hearts, bringing together the direct contact between 2 receptor signaling systems, forming an integrated and dynamic network. 36 
bAR EXPRESSION AND DENSITY
In cardiac tissues, there are 3 pharmacologically distinct subtypes of bARs. b 1 and b 2 AR stimulate adenylyl cyclase activity via Gs protein to produce cAMP, which binds to and activates PKA. This leads to phosphorylation of a number of targets including PLB, 37 troponin-I (TnI), 38 and L-type Ca 2+ channel, 39 all being responsible for cardiac contractile function. In healthy hearts and cardiomyocytes, b 1 ARs are responsible for catecholamine-induced increase in inotropy and lusitropy, whereas b 2 AR-specific ligands do not affect inotropy or lusitropy. 32, 33, 36, 40, 41 In the same light, b 1 AR-specific agonists promote phosphorylation of L-type Ca 2+ channel, 39 PLB, 37 ryanodine receptor 2, 42 and TnI 38 whereas b 2 AR-specific agonists only promote phosphorylation of L-type Ca 2+ channel 43, 44 in healthy cardiomyocytes. Fluorescent resonant energy transfer analysis of cAMP and PKA activity levels show that b 1 AR-specific stimulation produces robust signals, whereas b 2 AR-specific stimulation only produces small localized signals. 36, [45] [46] [47] Unlike b 1 and b 2 AR, b 3 AR decreases the contractile force in human ventricular muscle through activation of Gi protein and NO synthase signaling pathways. 48, 49 The activation of b 3 AR signaling involving both cAMP-and NO-dependent pathways may be a mechanism of preventing the overstimulation of heart muscle by catecholamine.
Although b 1 AR is the predominant adrenergic receptor isoform for increasing excitation-contraction coupling in healthy hearts, a diabetic state can lead to drastic changes in adrenergic signaling. In hearts from STZ-induced type 1 diabetes mellitus (T1DM) rats, one of the typical features observed is the decreased inotropic and chronotropic responses to bAR stimulation. [50] [51] [52] Accordingly, the mRNA and protein levels of b 1 AR in the hearts of STZ-induced diabetic rats and their function in promoting heart rate and contractility are decreased; and these alterations progress along with duration of DM. 53, 54 The reduction in myocardial b 1 AR numbers and mRNA is prevented by insulin therapy. [54] [55] [56] Interestingly, in the same diabetic model, while the b 2 AR mRNA level in the heart is increased, the density of b 2 AR protein, however, is decreased. 54 This could be because of an increased rate of b 2 AR degradation and/or decreased posttranslational modifications that prevent the maturation of the receptor along the secretory pathway. 54 Meanwhile, the mRNA and protein level of cardiac b 3 AR in 14-week STZ DM rats are twice of that in controls. 54 The estimated ratio of b 1 , b 2 , and b 3 AR proteins is approximately 62:30:8 and 40:36:23 in the heart of control and diabetic rats, respectively; and a 2-week insulin treatment of diabetic animals restored the ratio to 57:33:10. 54 These observations support a notion that the abnormality of cardiac response to catecholamines, especially in the case of T1DM, is because of the decrease in b 1 AR densities. However, controversial results have been observed in experimental T2DM. In T2DM rats, the responsiveness of 58 ; and bARs can be redistributed between the plasma membrane and the intracellular compartments. 59 The study in T1DM rats indicates that only the cell surface bAR number decreases, 59 which is closely associated with the diabetic state and is reversed by short-term insulin treatment. 59 Thus, the insulin-regulated bAR redistribution may play differential roles in the progress of cardiomyopathy in T1DM and T2DM. The complexities of bAR redistribution regulated by insulin in DCM will be further discussed in the section on receptor trafficking.
INSULIN-INDUCED bAR PHOSPHORYLATION
Agonist-induced phosphorylation of GPCRs at multiple sites by different kinases is a complex process which results in various signal outcomes. 60 In the case of bARs, studies have shown that both PKA 61 and GRK2 62 mediate receptor phosphorylation, but they vary in terms of mechanisms of activation, phosphorylation sites, and kinetics. 63 Insulin-induced PKA Phosphorylation of b 2 AR
Switches G protein Coupling
Stimulation of both b 1 and b 2 ARs leads to increase G smediated adenylyl cyclase activity and a subsequent increase in intracellular cAMP. 64, 65 The cAMP-dependent-activation of PKA phosphorylates both agonist-occupied and agonistfree receptors at sites within the third intracellular loops and C-terminal tails, which decreases the affinity of the receptor for G s . For b 2 AR, these phosphorylation events increase affinity for G i . 66 The switch of G protein binding affinity leads to inhibition of adenylyl cyclase and increased MAPK activation including the extracellular-regulated kinases p44
and p42 (ERK1/2), therefore, causing b 2 AR to have a different signaling profile from b 1 AR. [66] [67] [68] Recently, our group reported that in cardiomyocytes, insulin, like catecholamine, promotes PKA-mediated phosphorylation of b 2 AR at serine 261/262 sites. The phosphorylation of b 2 AR by PKA switches the receptor coupling from G s to G i protein, leading to an insulin-induced inhibitory effect on b 2 AR signal cascade 36 (Fig. 1) . Mechanistically, how insulin promotes PKA activity remains unclear. One possibility is that InsR undergoes autophosphorylation and activates IRS1/2 for subsequent activation of RAS/RAF/ MEK/ERK1/2 signaling cascade. 69 ERK can phosphorylate a consensus motif RXSP within the catalytic domains of PDE4B, PDE4C, and PDE4D. 70 ERK phosphorylation of the long form PDE4D3 reduces cAMP-hydrolytic activity (50% inhibition), which in turn leads to increased levels of cAMP for PKA activation. In cardiomyocytes, only the long PDE4D isoforms bind to b 2 AR, 71 indicating a potential role of these long isoforms in insulin-induced PKA phosphorylation of b 2 AR in hearts.
Insulin-induced GRK2 Phosphorylation of b 2 AR Promotes b-arrestin Recruitment and
Receptor Internalization
Although PKA phosphorylation of b 2 AR is sensitive to low levels of agonist stimulation, at a high occupancy of agonist, b 2 AR is also phosphorylated by GRK at distinct sites. [72] [73] [74] Recent studies suggest that GRK2 is emerging as a physiologically negative modulator of insulin signaling in skeletal muscle and adipose tissue, as hemizygous GRK2 FIGURE 1. Acute insulin signaling impairs cardiac adrenergic stimula-mice are protected from insulin resistance in multiple model systems. 75 Increased GRK2 abundance is observed in human hearts with metabolic syndrome and in different murine models of insulin resistance. 76 GRK2 can even be used as a biomarker that is consistently upregulated in human HF and animal models of HF. Genetically inhibiting GRK2 leads to cardiac protection in mice. 77 Higher levels of GRK2 can impair bAR-mediated inotropic reserve; its inhibition or molecular reduction improves pump function in animal models including a preclinical pig model of HF. 78 A recent study indicates that insulin can promote formation of IRS-GRK2 complexes in animal hearts. 79 However, the molecular basis underlying the deleterious effects of GRK2 in DCM is not fully understood. Previous study shows that GRK2-mediated phosphorylation of the b 2 AR is necessary for subsequent internalization in cardiomyocytes, 80 which contributes to compartmentalization of the G s -stimulated cAMP signal and selectively affects cardiac contractile. 81 In a recent study, we demonstrate that GRK2 may represent a molecular link between the InsR and bAR signaling for regulation of cardiac function ( signaling and myocyte contractility. 36 GRK phosphorylation also triggers the binding of arrestins to the activated receptors, which impairs G protein coupling to GPCRs such as b 2 AR in a process known as desensitization. 82 In contrast, phosphorylation of the b 2 AR at PKA/protein kinase C sites alone in vitro is not sufficient to promote arrestin recruitment. 83 Thus, signaling consequences of these phosphorylation events have overlapping features (eg, they both result in receptor desensitization), and unique properties (eg, phosphorylation by GRK, but not PKA, mediates arrestin recruitment and receptor internalization). 63, 84, 85 Mechanistically, insulin promotes GRK phosphorylation of b 2 AR via 2 possible pathways. Insulin stimulation leads to activation of G i protein, 86 a process releasing Gbg subunits, which is required for GRK activation by recruiting cytosolic GRKs to the plasma membrane near the b 2 ARs.
Alternatively, GRK2 binds to IRS1 via its C-tail. 79 Thus, the activated InsR recruits IRS1-GRK2 to the complex of Although a majority of GPCR phosphorylation happens in serine/threonine-rich regions, it also happens on tyrosine residues. [87] [88] [89] Studies show that tyrosine 350/354 and 364 in the cytoplasmic region of b 2 AR are primary targets of tyrosine kinases including InsR and insulin-like receptor. 15 Insulin stimulation increases b 2 AR phosphorylation on tyrosine, 24 which augments the action of insulin through promoting internalization of the b 2 AR. 18, 89, 90 Likewise, stimulation with insulin-like growth factor-1 (IGF-1), a hormone with similar molecular structure to insulin, promotes phosphorylation of b 2 AR in vivo predominantly on tyrosine 132/141 sites. IGF-1 also blocks bAR agonist action. 18 Meanwhile, stimulation of InsR promotes PI3K-mediated activation of Akt/PKB, which is able to directly phosphorylate b 2 AR at serine 345/346 on the C-terminal tail. 91 This Akt-mediated phosphorylation is required for the inhibitory effect of insulin on b-adrenergic stimulated cAMP accumulation in Chinese hamster ovary clones expressing wild-type b 2 AR, expressing either double mutation in b 2 AR (S345A/S346A) or the dominant-negative version of Akt (K179A/T308A/S473A) abolishing insulininduced inhibition of the cAMP response. 91 This ability of Akt/PKB to phosphorylate b 2 AR is also obligate on insulininduced tyrosine 350 phosphorylation in the receptor. 91 The phosphorylated tyrosine 350 creates an SH2 (src homology domain 2)-binding motif to promote the association of c-Src, Grb2, and dynamin. 87, 89, 92 The consequent binding of the adaptor molecule Grb2 to the phosphorylated b 2 AR leads to disruption of receptor-G protein coupling. 93 Therefore, the phosphorylation of b 2 AR at tyrosine 350 effectively precludes the b 2 AR from coupling to G s protein and further activation of adenylyl cyclase for cAMP generation. Mutation of tyrosine 350/354 to phenylalanine abolishes the ability of insulin to counter-regulate b-agonist stimulation of cAMP accumulation. 90 In addition, through a phosphorylated tyrosine-mediated binding to Grb2, the b 2 AR acts as a scaffold to promote signal pathways such as MAPK in the absence of its own ligand. 94 The binding to dynamin can also promote b 2 AR endocytosis. 89, 95 Currently, the studies on tyrosine phosphorylation are mostly done in DDT1-MF2 smooth muscle cells, human epidermoid carcinoma cells (A431), and Chinese hamster ovary cells. The information of tyrosine phosphorylation of b 2 AR in cardiac tissues remains unclear and awaits further determination.
INSULIN-INDUCED bAR TRAFFICKING AND INTERNALIZATION
Receptor phosphorylation and internalization are prominent features of agonist-induced desensitization of GRCRs. There are 2 types of desensitization based on the nature and types of kinases involved: homologous desensitization and heterologous desensitization. Chronic use of bAR agonists provokes homologous desensitization that limits the therapeutic use of the agonists. 96 Meanwhile, GPCRs can be subjected to heterologous desensitization when a different membrane receptor is stimulated. This heterologous stimulation can be mediated by another GPCR, an RTK, or a cytokine receptor. Indeed, insulin has been shown to induce desensitization and sequestration of bAR in a way similar to bAR agonists. 96 Earlier data show that in vitro incubation with insulin results in a reduction of the sensitivity of cardiac tissues to ISO without altering total bAR number. 97 In rat adipocytes, insulin induces an acute reduction in the ligand binding capacity of bARs because of a rapid and dose-dependent translocation of bARs to the interior of the cell. 98 Chronic insulin treatment also promotes b-arrestin-1 degradation, which is associated with decreased bAR agonist-mediated MAP kinase signaling. 99 Consistently, injection of insulin to healthy male subjects induces a reduction in b-adrenergic sensitivity, 100 which supports a hypothesis that reduced b-adrenergic sensitivity is an important pathophysiological mechanism in hypoglycemia in T1DM. 100 Mechanistically, Grb2 contains 1 SH2 domain and 2 SRC homology 3 (SH3) domains. After insulin stimulation, Grb2 can bind directly to b 2 AR via SH2-binding domain and can connect the receptor to p85 regulatory subunit of PI3K and dynamin via the SH3 domains. Both PI3K and dynamin are well documented in b 2 AR internalization. [101] [102] [103] [104] On the other side, activated InsR promotes phosphorylation of tyrosine 895 on IRS1, which also creates a high affinity and specific binding site for the SH2 domain of GRB2 and p85 of PI3K. Insulin also stimulates Src association with b 2 AR/AKAP250/PKA/protein kinase C complex. 105 These observations are in line with bAR agonist-induced and clathrin-mediated endocytosis, which requires Src-mediated tyrosine phosphorylation of dynamin. 106 Inhibition of Src blocks the ability of insulin to internalize b 2 AR and as well as translocate GLUT4 vesicles. 107 Together, the binding of phosphorylated tyrosine 350 of b 2 AR to SH2-domain proteins seems to act in concert with Akt/PKB phosphorylation of serine 345/346 to mediate b 2 AR internalization in response to insulin. 60, 89, 95 Moreover, IRS1 interacts with the C-terminus of GRK2 79 ; insulin stimulation induces GRK2 membrane translocation and increases the association of GRK2 and b 2 AR in an IRS2-dependent manner. 41 The IRS2-dependent recruitment of GRK2 is necessary to promote b 2 AR phosphorylation and internalization. 41 This together with enhanced phosphorylated b 2 AR coupling to inhibitory Gi proteins results in inhibition of bAR-activated AC-cAMP-PKA signaling and cardiac contraction. 41 IRS1 and IRS2 share significant homology, and the mechanism involved in the counter-regulation of insulin on bAR signaling in heart by individual IRS proteins remains to be determined.
Considering insulin-induced b 2 AR internalization uses many components that are widely shared by bAR agonistinduced internalization, such as PI3K, src, dynamin, etc., one would expect that a common pathway is involved in the b 2 AR trafficking in response to both stimuli. However, the fact that the Akt/PKB sites of phosphorylation on b 2 AR are different from those of the GRK sites 73, 91 suggests that the mechanism of receptor internalization is distinct from that mediated by the GRKs. 60 Accordingly, studies show that compared with bAR agonist-induced receptor internalization and recycling, the insulin-stimulated b 2 AR requires a distinct cytoskeletal system, in which the b 2 AR sequestration requires an intact actin cytoskeleton, and recycling to the cell surface requires intact microtubules. 108 In comparison with rapid and robust agonist-induced internalization of b 2 AR, the internalization of b 1 AR is limited. 109 
INSULIN ACTIVATES bAR

DOWNSTREAM EFFECTORS G i Protein
The influence of G i protein on RTK signaling was first proposed in 1987, based on the observation that experimentallyinduced diabetes leads to the loss of G i -protein expression in rat liver. 86 Since then, G i2 deficiency has been found to increase protein-tyrosine phosphatase activity and attenuate insulinstimulated tyrosine phosphorylation of IRS in vivo. Deletion of G ai2 in liver, skeletal muscle, and white adipose tissue of transgenic mice has been found to induce insulin resistance, 112 whereas tissue-specific expression of a constitutively active mutant of G i2 in skeletal muscle, liver, and adipose tissues markedly activates translocation of the insulin-sensitive GLUT4 glucose transporter to the cell surface 113 and enhances glucosetolerance of transgenic mice. 114 All the evidence implicates G ai2 as a positive regulator of insulin action.
Mechanistically, it was demonstrated that G ai2 interacts with InsR during insulin signaling. 115 Studies have suggested that this association participates in the regulation of InsR autophosphorylation, yet, the mechanisms are controversial. For instance, it has been shown that GTPgs increases the autophosphorylation of partially purified cardiac InsRs. 116 In contrast, an inhibition of RTK activity by GTPgs has been observed in InsR preparations from rat adipocytes. 117 The discrepancy could be because of the conditions used in the experiments. Overall, InsRs can functionally engage G proteins for downstream signaling, similar to GPCRs. In the same vein, a recent finding shows that in cardiomyocytes, insulin promotes b 2 AR coupling to G i ; and inhibition of G i by pertussis toxin abolishes the inhibitory effect of insulin on b 2 AR and downstream cAMP-PKA signal cascade. 36 
Phosphodiesterase
We have discussed how acute insulin treatment alters the function of the stimulatory pathway of adenylyl cyclases by uncoupling b 2 AR from its cognate G protein, which leads to a decrease in cAMP production. Meanwhile, cyclic AMP dependent phosphodiesterases (PDEs) provide additional mechanisms for attenuation of cAMP signal. 118 Interestingly, in rat adipocytes, ISO and insulin increase activity of distinct pools of PDE to modulate subcellular cAMP and PKA activity. With cotreatment with insulin and ISO, there is a rapid, transient, and synergistic activation of particulate cAMP PDE, which temporally correlates with a decrease in PKA activity and reduction in lipolysis. 119 Moreover, among PDE isoforms expressed in 3T3-L1 and primary mouse adipocytes, only PDE3B and PDE4D are upregulated by longterm treatment with insulin in a PI3K-dependent manner. In contrast, long-term treatment with bAR agonist induced down-regulation of PDE3B and upregulation of PDE4D. 120 In line with the observation in adipocytes, our recent study shows that in rodent hearts, hyperinsulinemia induces upregulation of PDE4D protein expression and activity, which correlates with cardiac dysfunction 121 (Fig. 2) .
OTHER GPCRs CROSS-TALK WITH INSULIN SIGNALING PATHWAY
The cross-talk between insulin and angiotensin II (Ang II) signaling pathway has gained great focus because of the significant clinical association between type 2 diabetes and hypertension. 122 The cross-talk could happen at different levels. At early steps, Ang II activates JAK and in turn promotes tyrosine phosphorylation of IRS-1 and IRS-2, these events happen in a large signaling complex formed with angiotensin receptor type 1 (AT1R). 123, 124 However, in contrast to the effect of insulin, Ang II inhibits PI3K activity associated with phosphorylated IRS-1 and IRS2, 123 suggesting that Ang II can block insulin signaling partially via the PI3K pathway; Likewise, Ang II increase serine phosphorylation of the b-subunit of the insulin receptor and IRS-1, which is another mechanism for the inhibition of insulin signaling. [124] [125] [126] [127] Thus, multiple serine phosphorylation events are involving in the negative modulation of Ang II on insulin signaling. In the downstream signal events, Ang II could promote the induction of SOCS-3, which interacts and inhibits insulin signal transduction through the IR and IRS proteins or JAK/STAT signal pathway. [128] [129] [130] In addition, activation of AT1R by binding to Ang II promotes activation of ERK1/2 and JNK, which can phosphorylate IRS-1, impairing the transduction of insulin signaling to promote NO production by eNOS. [131] [132] [133] In parallel, Ang II also impairs insulin signal transduction through the IRS-PI3K-Akt pathway, which is consistent with the observation of the association of insulin resistance with cardiac hypertrophy. 134 Serotonin and insulin are key regulators of energy hemostasis in the hypothalamus. Under a diabetic situation, an impairment of the serotonergic signaling in the hypothalamus is observed. Moreover, hypothalamic impairment of the serotonin induced-PI3K/Akt pathway can modify downstream signaling cascades, leading to symptoms of type 2 diabetes. 135 These observations suggest the existence of a cross-talk between serotonin and insulin in the central nervous system (CNS).
THERAPEUTIC INTERVENTIONS
Targeting the Cross-Talk Between Insulin and bAR Signaling in Heart Under physiological conditions, insulin promotes glucose uptake, reduces myocardial O 2 consumption, and increases cardiac efficiency. 136 Moreover, insulin directly acts on heart muscle to augment cardiomyocyte contraction, which is mediated principally through the Akt/PKB signal pathway. 136 Several animal studies have shown the protective effects of insulin on the heart. 137 A recent study shows that insulin decreased necrosis in cardiomyocytes during ischemia through an Akt/NFkB pathway. 138 The beneficial effect of insulin in the postischemic functional improvement in responding to bAR agonist is likely because of the increased cell survival and subsequent more functional cardiomyocytes available within the I/R hearts. 25 However, such "acute" protection by insulin in I/R hearts cannot explain the absence of a benefit with hyperinsulinemia in the development of HF in DM independent of myocardial ischemia. 139, 140 Moreover, during chronic HF induced by pressure overload and myocardial infarction, cardiac tissues display a feature of insulin resistance. 10 Thus, many of the interactions between chronic insulin resistance and HF might differ from those of the beneficial effect in "acute" I/R in hearts.
The cardiac performance in cardiomyocyte-selective InsR knockout is mildly impaired, but absence of InsR signaling in the cardiomyocytes leads to worsening catecholamine-mediated myocardial injury. 30, 141 On the other side, despite the resistance in insulin-induced Akt activity, the excessive basal cardiac insulin signaling is detrimental and can exacerbate systolic dysfunction induced by pressure overload in mice. 142 Moreover, recent clinical therapy of diabetic medications (eg, glyburide) in HF patients show adverse effects, 143, 144 suggesting that aggressive metabolic controls with insulin secretagogues may exacerbate cardiac symptoms by driving InsR-mediated desensitization of adrenergic signal.
In this notion, insulin can drive desensitization of b 2 AR in the heart independent of sympathetic drive, offering an explanation on insensitivity of diabetic patients to b-blocker therapy.
Together, these studies indicate that acute insulin exposure inhibits b-adrenergic signaling by a mechanism that differs from the chronic insulin exposure in HF. The crosstalk between insulin and bAR signaling in DCM is complex and multifactorial. It is necessary to take consideration of both HF stages and insulin resistance in treatment on individual patients with comorbidity of diabetes and HF.
Other GPCRs as Therapeutic Targets in Diabetes and Diabetic Complications
The pharmaceutical therapeutic options for diabetes have traditionally targeted insulin receptor (insulin), kinases, or ion channels (sulfonylureas and metformin). However, recently several new therapies for diabetes that target GPCRs have been identified. These include Glucagon-like peptide 1 (GLP-1) based agonists and the related DPP-IV inhibitors, D2 dopamine receptor agonist, serotonin agonists, and more recently, GPR40 agonists and selective endothelin-A receptor antagonists.
The most well-developed therapies targeting GPCRs are GLP-1 agonists and the related DPP4 inhibitors. GLP-1 is a peptide hormone that is produced in the intestine after a meal. GLP-1 stimulates insulin secretion, inhibits glucagon secretion via activation of GLP-1 receptor, a member of GPCR family. 145, 146 However, the half-life of GLP-1 is very short primarily because of its degradation by the enzyme dipeptidyl peptidase IV (DPP-IV). Thus, efforts to extend the half-life of GLP-1 agonists include replacement of mimetic form of GLP-1 such as Exendin-4 and modification of natural GLP-1 structure, which aim for more resistant to DPP-IV degradation. [147] [148] [149] [150] On the other side, by prolonging endogenous GLP-1 concentrations and increasing fasting levels of GLP-1, DPP-IV inhibitors have also been used as adjuvant treatment for diabetes. [151] [152] [153] Meanwhile, free fatty acids have also been reported to stimulate insulin secretion in a glucose-dependent manner by activation of GPR40 (free fatty acid receptor 1 or FFAR1). [154] [155] [156] Thus, several GPR40 agonists are being developed such as TAK-875, which was shown both in rodents and humans to enhance insulin secretion and promote glucose control. 155, 157 Endothelin-1 (ET-1) is a peptide with vasoconstrictor activity, and ET-1 is implicated in the pathogenesis of hypertension, diabetes mellitus, and cardiovascular diseases. 158, 159 Plasma ET-1 levels have been shown to be elevated in animal diabetic models and the activity of ET-A receptors is enhanced in diabetic patients. 160 Thus, the therapeutic intervention designed to suppress the ET system may be effective in preventing the development of diabetic complications. Indeed, ET blockade is effective in improving cardiac dysfunction in the diabetic rats 161 and ameliorate experimental diabetic nephropathy. [162] [163] [164] The CNS is of importance to regulate whole body energy homeostasis. Endogenous dopaminergic and serotonergic rhythms in the CNS are reported to be involved in the transition from insulin-sensitive to insulin-resistant state. Within the ventromedial hypothalamus, serotonin level and activity are increased during insulin-resistant state and decrease to normal with return to insulin-sensitive state in animals that undergo seasonal changes in metabolism. Conversely, dopamine levels are low during an insulin-resistant state and increase to normal after return of the insulin-sensitive state. The D2 dopamine receptor agonist, bromocriptine, was approved for the treatment of type 2 diabetes recently. 165 Bromocriptine augments low hypothalamic dopamine levels and inhibits excessive sympathetic tone within the CNS, resulting in a reduction in post meal plasma glucose levels, because of enhanced suppression of hepatic glucose production. 165 Meanwhile, a peripheral serotonin inhibitor (LP-533401) has already been patented for treating diabetes and obesity, 166 suggesting that in peripheral tissues, suppressing serotonin signaling might represent a new target for treating diabetes by improving insulin resistance. 167, 168 
CONCLUSION
With diabetes and HF being common comorbid conditions, it is highly important to develop treatments for diabetic-related HF. Currently, we have learned that activation of the InsR pathway can lead to a desensitization of the cardiac adrenergic signaling pathway, which contributes to cardiac pathophysiology associated with diabetes. Although InsR and b 2 AR form a direct membrane receptor complex, additional important nodes where signaling cross-talk takes place between the adrenergic and insulin pathways are the G i and GRK2 proteins. A better understanding the cross-talk between these 2 cascades will allow us to develop more effective treatment strategies for patients with comorbidity of diabetes and cardiovascular complications.
